UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vaccine development for emerging infectious diseases

Nature medicine, 2021-04, Vol.27 (4), p.591-600

2021

Volltextzugriff (PDF)

Current and future cholera vaccines

Vaccine, 2020-02, Vol.38, p.A118-A126

2020

Volltextzugriff (PDF)

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection

Annual review of medicine, 2015-01, Vol.66 (1), p.423-437

2015

Volltextzugriff (PDF)

Novel prime-boost vaccine strategies against HIV-1

Expert review of vaccines, 2019-08, Vol.18 (8), p.765-779

2019

Volltextzugriff (PDF)

Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

Journal of medical virology, 2022-03, Vol.94 (3), p.1085-1095

2022

Volltextzugriff (PDF)

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines

Clinical and vaccine immunology, 2014-08, Vol.21 (8), p.1023-1036

2014

Volltextzugriff (PDF)

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial

Vaccine, 2024-07, Vol.42 (19), p.3999-4010

2024

Volltextzugriff (PDF)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

Vaccine, 2022-08, Vol.40 (35), p.5263-5274

2022

Volltextzugriff (PDF)

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

Vaccine, 2021-05, Vol.39 (22), p.3067-3080

2021

Volltextzugriff (PDF)

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial

The Lancet infectious diseases, 2018-06, Vol.18 (6), p.666-674

2018

Volltextzugriff (PDF)

Correlates of immunity to Group A Streptococcus: a pathway to vaccine development

npj vaccines, 2023-01, Vol.8 (1), p.1-7, Article 1

2023

Volltextzugriff (PDF)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines

Vaccine, 2020-07, Vol.38 (34), p.5556-5561

2020

Volltextzugriff (PDF)

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Vaccine, 2020-11, Vol.38 (49), p.7702-7707

2020

Volltextzugriff (PDF)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

Vaccine, 2020-11, Vol.38 (49), p.7708-7715

2020

Volltextzugriff (PDF)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

Vaccine, 2020-09, Vol.38 (39), p.6184-6189

2020

Volltextzugriff (PDF)

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines

Vaccine, 2020-07, Vol.38 (35), p.5734-5739

2020

Volltextzugriff (PDF)

Molecular epidemiology of a primarily MSM acute HIV‐1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia

Journal of the International AIDS Society, 2018-11, Vol.21 (11), p.e25204-n/a

2018

Volltextzugriff (PDF)

The Streptococcus pyogenes vaccine landscape

npj vaccines, 2023-02, Vol.8 (1), p.16-16, Article 16

2023

Volltextzugriff (PDF)

Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children

Vaccine, 2018-06, Vol.36 (26), p.3794-3801

2018

Volltextzugriff (PDF)

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report

Vaccine, 2020-06, Vol.38 (28), p.4476-4483

2020

Volltextzugriff (PDF)

Factors, enablers and challenges for COVID-19 vaccine development

BMJ global health, 2023-06, Vol.8 (6), p.e011879

2023

Volltextzugriff (PDF)

Vaccine access, equity and justice: COVID-19 vaccines and vaccination

BMJ global health, 2023-06, Vol.8 (6), p.e011881

2023

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(117)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(82)
Humans
(61)
Immunology
(61)
Vaccines
(40)
Infectious Diseases
(39)
Medicine, Research & Experimental
(27)
Research & Experimental Medicine
(27)
Female
(24)
Aids Vaccines - Immunology
(23)
Male
(22)
Vaccination
(22)
Microbiology
(20)
Adult
(19)
Hiv
(19)
Hiv Infections - Prevention & Control
(19)
Virology
(19)
Biological And Medical Sciences
(18)
Immunization
(18)
Hiv-1 - Immunology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Vaccine development for emerging infectious diseases

Current and future cholera vaccines

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection

Novel prime-boost vaccine strategies against HIV-1

Comparative safety of mRNA COVID‐19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial

Correlates of immunity to Group A Streptococcus: a pathway to vaccine development

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines

Molecular epidemiology of a primarily MSM acute HIV‐1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia

The Streptococcus pyogenes vaccine landscape

Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report

A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh

Factors, enablers and challenges for COVID-19 vaccine development

Vaccine access, equity and justice: COVID-19 vaccines and vaccination

Aktive Filter

Suchergebnisse filtern